Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-1/A IPO registration
- 1.1 EX-1.1
- 3.1.3 EX-3.1.3
- 3.2 EX-3.2
- 3.4 EX-3.4
- 4.1 EX-4.1
- 4.2 EX-4.2
- 4.3 EX-4.3
- 5.1 EX-5.1
- 10.1 EX-10.1
- 10.2.1 EX-10.2.1
- 10.2.2 EX-10.2.2
- 10.3.1 EX-10.3.1
- 10.3.2 EX-10.3.2
- 10.4.1 EX-10.4.1
- 10.4.2 EX-10.4.2
- 10.5 EX-10.5
- 10.6 EX-10.6
- 10.7 EX-10.7
- 10.8 EX-10.8
- 10.9 EX-10.9
- 10.10 EX-10.10
- 23.1 EX-23.1
- 23.2 EX-23.2
Associated filings
- 16 Feb 21 424B4 Prospectus supplement with pricing info
- 12 Feb 21 EFFECT Notice of effectiveness
- 11 Feb 21 S-1/A IPO registration (amended)
-
8 Feb 21 S-1/A IPO registration (amended)
- 19 Jan 21 S-1 IPO registration
NEXI similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated July 13, 2020 (except Note 16(e) as to which the date is February 8, 2021), in Amendment No. 1 of the Registration Statement (Form S-1 No. 333-252220) and related Prospectus of NexImmune, Inc. for the registration of its common stock.
/s/ Ernst & Young LLP
Tysons, Virginia
February 8, 2021